Johnson & Johnson(JNJ)
Drug Manufacturers - General · New Brunswick, NJ
$273.41+2.30 (+0.85%)
Delayed quote: Aug 19, 2026, 4:00 PM EDT
Drug Manufacturers - General · New Brunswick, NJ
Delayed quote: Aug 19, 2026, 4:00 PM EDT
Full-size annual and quarterly year-over-year growth charts for revenue, EPS, operating cash flow, EBITDA, and free cash flow against the 15%, 20%, and 30% bars over 3-, 5-, and 10-year windows, with each metric's valuation multiple vs its own history.
Revenue · 10YDoes not currently clear the 15%+, 20%+, or 30%+ revenue bars over 10Y.
Annualized revenue (TTM) · by quarter, last 40
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
| Metric | 10Y CAGR | Median YoY | YoY σ | Qtrs ≥ 20% | Neg. qtrs |
|---|---|---|---|---|---|
| RevenueRevenue | 3% | 3.9% | 7.7pp | 1 of 40 | 7 |
| EPSEPS | 7.3% | 4.5% | 99.7pp | 14 of 37 | 16 |
| Op cash flowOperating cash flow | 2.4% | 4.8% | 23.8pp | 10 of 40 | 16 |
| EBITDAEBITDA | 4.2% | 2.7% | 12.4pp | 4 of 40 | 13 |
| FCFFree cash flow | 2.2% | 3.3% | 34.0pp | 13 of 40 | 18 |
Reported figures over 10Y: annual-series CAGR, median and standard deviation (σ, percentage points) of quarterly year-over-year growth, quarters at or above 20%, and quarters with negative YoY. “—” means the window needs more comparable data.
Scores, qualification bars, and the 0–100 consistency methodology are documented on the compounders list page →
See also: JNJ on the compounders surface · All compounders, ranked